Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
Department of Urology, China-Japan Friendship Hospital, Beijing, China.
BMJ Open. 2019 Apr 20;9(4):e025871. doi: 10.1136/bmjopen-2018-025871.
The purpose of this study was to systematically review the outcomes of the use of one-shot dilation (OSD) and serial tract dilation for percutaneous nephrolithotomy (PCNL).
A systematic review and meta-analysis was conducted. The randomised controlled trials (RCTs) included in the study were identified from EMBASE, MEDLINE and the Cochrane Central Register of Controlled Trials. The last search was performed on 30 April 2018. Summary effects were calculated as risk ratios (RRs) with 95% CIs or mean differences (MDs) with 95% CIs. The endpoints included access time, fluoroscopy time, successful dilation rate, stone-free rate, postoperative decrease in haemoglobin levels, transfusion rate, complication rate and length of postoperative hospital stay.
A total of seven RCTs were included in the study, with clinical data reported for 697 patients. The overall access time was approximately 110 s shorter in the OSD group than in the serial dilation group (MD, -110.14; 95% CI -161.99 to -58.30; p<0.0001). The fluoroscopy time was shorter with OSD in all RCTs. In addition, the decrease in postoperative haemoglobin levels was approximately 2.3g/L less in patients in the OSD group than in those in the serial dilation group (MD, -0.23; 95% CI-0.39 to -0.07; p=0.004). No relationship was found between the successful dilation rate, stone-free rate, transfusion rate, or complication rate and the method of tract dilation.
OSD is a safe and efficacious tract dilation technique that can reduce the access time, fluoroscopy time and postoperative decrease in haemoglobin level. No difference was found in the successful dilation rate, stone-free rate, transfusion rate or rate of complications between the OSD and serial dilation groups. The difference in the length of postoperative hospital stay was uncertain. OSD may be a better method of tract creation for PCNL.
本研究旨在系统回顾单次扩张(OSD)与经皮肾镜取石术(PCNL)连续通道扩张的效果。
进行了系统评价和荟萃分析。研究中纳入的随机对照试验(RCT)来自 EMBASE、MEDLINE 和 Cochrane 对照试验中心注册库。最后一次检索时间为 2018 年 4 月 30 日。汇总效应以风险比(RR)和 95%置信区间(CI)或均数差值(MD)和 95%CI 表示。终点包括通道建立时间、透视时间、扩张成功率、结石清除率、术后血红蛋白水平下降、输血率、并发症发生率和术后住院时间。
本研究纳入了 7 项 RCT,共报道了 697 例患者的临床数据。与连续扩张组相比,OSD 组的总体通道建立时间缩短了约 110s(MD,-110.14;95%CI-161.99 至-58.30;p<0.0001)。所有 RCT 中,OSD 组的透视时间均较短。此外,与连续扩张组相比,OSD 组患者术后血红蛋白水平下降约 2.3g/L(MD,-0.23;95%CI-0.39 至-0.07;p=0.004)。通道扩张方式与扩张成功率、结石清除率、输血率或并发症发生率之间未见相关性。
OSD 是一种安全有效的通道扩张技术,可缩短通道建立时间、透视时间和术后血红蛋白水平下降。OSD 组和连续扩张组的扩张成功率、结石清除率、输血率或并发症发生率无差异。术后住院时间的差异不确定。OSD 可能是 PCNL 更好的通道建立方法。